Detection of recurrence of HPV-driven oropharyngeal cancer by HPV cell-free DNA
Plasma HPV DNA detected recurring throat cancer months before clinical symptoms in early testing, suggesting a scalable surveillance tool for this growing cancer type.
Plasma HPV cfDNA quantified by multiplex digital PCR demonstrated excellent diagnostic accuracy at HPV-OPC diagnosis and detected impending recurrence 3–8 months before clinical detection in 2 patients in this prospective cohort of 59. While limited recurrence events constrain PPV estimates, the finding supports HPV cfDNA as a scalable, minimally invasive surveillance biomarker for an increasingly prevalent cancer subtype.
What the study was
- Study design
- Prospective cohort study
- Population
- HPV-OPC patients, post-treatment surveillance
- Sample size
- 59
- Category
- Early Detection
- Maturity
- Validated
- Journal
- Scientific Reports
Why it surfaced
Prospective cohort; pre-clinical recurrence signal 3–8 months early; HPV-OPC incidence rising; DKFZ/University Hospital Zurich collaboration.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.